1. Home
  2. EB vs CLLS Comparison

EB vs CLLS Comparison

Compare EB & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EB
  • CLLS
  • Stock Information
  • Founded
  • EB 2003
  • CLLS 1999
  • Country
  • EB United States
  • CLLS France
  • Employees
  • EB N/A
  • CLLS N/A
  • Industry
  • EB EDP Services
  • CLLS Biotechnology: Pharmaceutical Preparations
  • Sector
  • EB Technology
  • CLLS Health Care
  • Exchange
  • EB Nasdaq
  • CLLS Nasdaq
  • Market Cap
  • EB 235.9M
  • CLLS 260.8M
  • IPO Year
  • EB 2018
  • CLLS 2007
  • Fundamental
  • Price
  • EB $2.63
  • CLLS $2.85
  • Analyst Decision
  • EB Buy
  • CLLS Buy
  • Analyst Count
  • EB 2
  • CLLS 1
  • Target Price
  • EB $5.25
  • CLLS $4.00
  • AVG Volume (30 Days)
  • EB 838.3K
  • CLLS 285.2K
  • Earning Date
  • EB 08-07-2025
  • CLLS 08-04-2025
  • Dividend Yield
  • EB N/A
  • CLLS N/A
  • EPS Growth
  • EB N/A
  • CLLS N/A
  • EPS
  • EB N/A
  • CLLS N/A
  • Revenue
  • EB $300,856,000.00
  • CLLS $63,438,000.00
  • Revenue This Year
  • EB N/A
  • CLLS N/A
  • Revenue Next Year
  • EB $11.64
  • CLLS $4.90
  • P/E Ratio
  • EB N/A
  • CLLS N/A
  • Revenue Growth
  • EB N/A
  • CLLS 223.09
  • 52 Week Low
  • EB $1.81
  • CLLS $1.10
  • 52 Week High
  • EB $4.12
  • CLLS $3.24
  • Technical
  • Relative Strength Index (RSI)
  • EB 56.83
  • CLLS 62.05
  • Support Level
  • EB $2.21
  • CLLS $2.70
  • Resistance Level
  • EB $2.68
  • CLLS $2.81
  • Average True Range (ATR)
  • EB 0.14
  • CLLS 0.27
  • MACD
  • EB 0.03
  • CLLS -0.01
  • Stochastic Oscillator
  • EB 84.00
  • CLLS 51.85

About EB Eventbrite Inc.

Eventbrite Inc is a self-service ticketing and experience technology platform that serves event creators. The company's two-sided marketplace connects creators and consumers every month to share their passions, artistry, and causes through live experiences. Creators use its self-service ticketing and marketing tools to plan, promote, and sell tickets to their events, and event seekers use its website and mobile application to discover and purchase tickets to experiences. Geographically, it generates maximum revenue from the United States. The company generates revenues principally from service fees and payment processing fees from the sale of paid tickets on its platform.

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Share on Social Networks: